Ritlecitinib Generally Safe and Tolerated for Alopecia Areata
The ALLEGRO study detailed the efficacy and safety of ritlecitinib in adult and adolescent patients with the alopecia areata.
Dupilumab, Biologics for the Youngest Atopic Dermatitis Patients
The agent may become approved this year for children aged 6 months to 5 years old. Amy S. Paller, MD, discusses what impact it could bring.
Detailing Potential Dermatology Drug Approvals from AAD 2022
Dr. Raj Chovatiya provides updates from AAD on some pending and potential FDA approvals for several dermatology therapies.
Baricitinib Treatment Leads to Hair Regrowth in Alopecia Areata
With no approved therapies currently available, Dr. Brett King feels that the JAK inhibitor baricitinib could provide patients with a long sought after solution to hair loss.
Topical Gene Therapy B-VEC Reaches Phase 3 Efficacy Endpoints for DEB Disease Reversal
New AAD 2022 data show the novel gene therapy from Krystal Biotech provided wound healing by 3 months in patients with dystrophic epidermolysis bullosa.
The Potential of Dupilumab Treatment for Prurigo Nodularis
Dr. Gil Yosipovitch suspects that dupilumab will be approved for use in patients with prurigo nodularis based on new data from the LIBERTY-RN PRIME2 trial.
Amy S. Paller, MD: Systemic Atopic Dermatitis Therapy for Pediatric Patients
The Feinberg School of Medicine expert discusses the impact of dupilumab and other biologics on severely affected children and adolescnets.
How Autoimmune Disease Risks Heightens After SARS-CoV-2
An expert delves into the increased risk of conditions including psoriasis flares, lupus, and scleroderma following COVID-19.
Addressing Cardiometabolic Disease in Patients with Psoriasis
New phase 4 data suggests that apremilast could be used to improve cardiometabolic function in patients with psoriatic disease.
Positive Long-Term Safety Data for Tralokinumab in Patients with AD
Data from the 5-year extension trial ECZTEND indicated that the overall safety profile of tralokinumab was consistent with the previous ECZTRA trials.
The Promise of Ruxolitinib Cream for Vitiligo Repigmentation
Dr. David Rosmarin follows up his AAD presentation with an interview on ruxolitinib cream for facial and body repigmentation in patients with vitiligo.
Awaiting FDA Decision on Ruxolitinib Cream for Vitiligo
John E. Harris, MD, PhD, discusses the delayed decision date for the topical JAK inhibitor, and what more needs to be researched on the drug.
The Promising Future of Vitiligo Treatment
John E. Harris, MD, PhD, explains how JAK inhibitors and biologic therapy may advance the field from "Iron Age" era treatment strategy.
Atopic Dermatitis Linked to Increased Risk of Select Cancers
The increased risk of cancer development in patients with atopic dermatitis has been suggested due to chronic inflammation or immunologic defects inherent to the disease and various treatments.
VISIBLE Study Dedicated Entirely to Psoriasis Patients with Skin of Color
Dr. Daphne Chan spoke of representation in psoriasis trials, how psoriasis affects different skin types, and how the VISIBLE study can influence dermatology research at large.
Jan Wehkamp, MD, PhD: The Promise of Biologics for IBD
The advent of biologics has transformed care for patients with inflammatory bowel disease.
Institutional Perspectives in Psychiatry: Addressing Challenges in Depression Treatment
Subhdeep Virk, MBBS, chaired the recent State of the Science event on treatment-resistant depression.
The Impact of a Pegcetacoplan FDA Approval for Geographic Atrophy
After more promising long-term data, Apellis announced plans to seek regulatory approval. An investigator explains what value it could bring to patients.
Axel Dignass, MD, PhD: The Promising Future of Guselkumab
Approximately 60% of patients with ulcerative colitis treated with guselkumab achieved clinical remission.
FT218 Improves Sleep Quality, Daytime Sleepiness in Narcolepsy Patients
New data on FT218 will be presented at the World Sleep 2022 conference in Rome.
Alon Avidan, MD, MPH: Promising Sleep Therapies
Dr. Avidan speaks of the increased prevalence of insomnia and sleep-wake patterns and promising new therapies for sleep disorders including narcolepsy.
Using Smart Bed Technology to Approximate Influenza-Like Illness
Dr. Garcia-Molina speaks to how smart bed technology can unobtrusively collect data to predict and track the development of symptoms associated with respiratory illnesses.
Larry Allen, MD: Personalizing Current and Future Heart Failure Therapies
The University of Colorado expert joins for a 5-part interview on making sense of the boom of new agents and care strategies.
Nihar Desai, MD, MPH: Improving PCSK9 Inhibitor Use, Guiding Heart Failure Care & ACC 2022 Headlines
The Yale Associate Chief of Cardiovascular Medicine discusses improved use of available drug classes, as well as the potential approval for omecamtiv mecarbil.
Seth Martin, MD, MHS: How Technology Is Shaping Preventive Cardiology
The Johns Hopkins expert details recent advances in remote cardiovascular care and research, and explains how the field will continue to evolve.
Xingbin Ai, PhD: How the Nervous System Influences Pediatric Asthma
By blocking certain neurogenic changes that occur in the lungs at childhood, patients may avoid asthma and allergic responses into adulthood.
Debajyoti Ghosh, PhD: Antibiotic Exposure in Pregnant Women and AD Development in Offspring
Currently, antibiotics comprise roughly 80% of prescribed pregnancy medications, and recent epidemiological studies have indicated a link between antibiotic use and dysbiosis.
Rasika Mathias, PhD: Detailing the LEAP Study
Dr. Mathias noted that investigators are continuing to determine if age plays a role in peanut allergy risk and sensitization.
Juan Carlos Cardet, MD: PARTICS Reduces Asthma Disparities in Black and Latino Communities
The study found that PARTICS, in addition to the usual care these patients received, reduced severe asthma exacerbations by 15.4% (p50.048) which corresponded to a reduction of 13 exacerbations/100 patient-years.
Sara Anvari, MD, MSc: Urticaria and Angioedema Events Following COVID-19 Vaccination
Most cases had onset after 4 hours and were mild, which Dr. Anvari noted should not contraindicate future COVID-19 vaccine doses.
2 Clarke Drive Cranbury, NJ 08512